MOTS-c Peptide Dosage Protocol: What Research Actually Shows

Research protocols for MOTS-c typically describe 5 to 10 mg per week, split into two or three subcutaneous injections, and run for 4 to 8 weeks. MOTS-c is not FDA-approved for human use, and no human clinical trial has established an official dose. Everything below reflects how animal studies and community protocols are structured, not a medical recommendation.

What MOTS-c Is and Why Dosing Is Hard to Pin Down

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded in the 12S rRNA region of mitochondrial DNA. Rodent studies link it to better insulin sensitivity, increased glucose uptake, and improved exercise capacity.

Human evidence is limited. Small trials show that exercise raises naturally occurring MOTS-c levels, but no phase I study has published a half-life, clearance rate, or dose-response curve for the injected peptide. Without that data, most protocols borrow the logic used for other short-half-life peptides.

Common MOTS-c Peptide Dosage Protocol Ranges

Most protocols discussed in research circles fall between 5 mg and 10 mg per week. The table below shows the patterns that appear most often.

Protocol Style	Weekly Dose	Typical Frequency	Cycle Length
Conservative first run	5 mg	2.5 mg twice weekly	4 weeks
Standard research range	10 mg	5 mg twice weekly	4-8 weeks
Split daily	10 mg	1-2 mg daily	4-6 weeks
Higher-frequency	15 mg	5 mg three times weekly	4 weeks

These figures are not validated human doses. They are ranges that appear in animal extrapolations and self-reported community logs, and they vary widely between sources.

Injection Frequency: Daily, Every Other Day, or Twice Weekly

Frequency usually depends on how the user wants to manage a short half-life. Because MOTS-c is thought to clear quickly, many protocols split the weekly total into smaller, more frequent doses.

• Twice weekly: 5 mg per injection, often Monday and Thursday.
• Every other day: roughly 2 to 3 mg per injection.
• Daily: 1 to 2 mg per injection, usually first thing in the morning.

Where the peptide is injected

Subcutaneous injection into the abdomen or upper thigh is the standard route described in protocols. Typical equipment is a 29- to 31-gauge insulin syringe. Injection sites should be rotated to reduce irritation.

Cycle Length, Timing, and Time Off

Most protocols run 4 to 8 weeks, then pause for at least 4 weeks. A longer 12-week run appears in some logs, but no data supports it.

Timing is usually morning and, in many cases, fasted. That choice comes from rodent data showing MOTS-c activity overlaps with fasting and exercise metabolism, not from human trial design.

If you have seen a document labeled "mots-c dosage protocol pdf" shared in forums, treat it as a template rather than an authority. The same weekly totals appear across most of those files, with the frequency and cycle length swapped around.

Reconstitution and Injection Basics

MOTS-c ships as a lyophilized powder and must be reconstituted before use. A common approach mixes a 10 mg vial with 2 mL of bacteriostatic water, which yields 5 mg per mL.

1. Swab the vial stopper with alcohol and let it dry.
2. Inject the water slowly down the inside wall of the vial to avoid foaming.
3. Swirl gently; do not shake.
4. Store the reconstituted solution in the refrigerator and keep the dry powder frozen.

Cloudy, discolored, or particle-filled solutions should be discarded.

MOTS-c Compared With Other Research Peptides

MOTS-c is one of several mitochondrial-targeted peptides under study. SS-31, also called elamipretide, acts on cardiolipin at the inner mitochondrial membrane, while MOTS-c works through AMPK signaling. The two are often compared, so people researching an ss-31 peptide injection dosage frequently end up reading about MOTS-c in the same sitting.

Dosing logic does not transfer cleanly between compounds. An aod 9604 dosage protocol, for example, uses a much smaller milligram range because AOD-9604 acts on fat metabolism through a different pathway entirely.

Peptides with unrelated goals should not be stacked on the same schedule without clinical oversight. A dsip dosage protocol designed around sleep architecture, for instance, has nothing in common with a metabolic peptide schedule.

Safety, Side Effects, and Legal Status

MOTS-c is not approved by the FDA for human use and is sold as a research chemical only. Vials labeled "not for human consumption" are the norm, and purity varies by vendor.

Reported side effects in community logs include injection site reactions, headache, fatigue, and occasional lightheadedness. Because the peptide influences glucose metabolism, a theoretical risk of hypoglycemia exists, especially when combined with fasting or diabetes medication.

Anyone using or considering MOTS-c should do so under medical supervision, with baseline and follow-up bloodwork covering glucose, liver enzymes, and metabolic markers. Pregnant or breastfeeding individuals and anyone taking prescription medication should avoid it.

If you are searching for a general mot c peptide dosage reference, the honest answer is that no verified human dose exists. Every number in circulation is an estimate.

COMMON QUESTIONS

Frequently Asked Questions

What is the typical MOTS-c peptide dosage protocol?

Most protocols describe 5 to 10 mg per week split into two or three subcutaneous injections over a 4- to 8-week cycle. No human clinical trial has established a safe or effective dose, so these numbers are estimates rather than medical guidance. Anyone considering MOTS-c should discuss it with a licensed healthcare professional first.

How long can you run MOTS-c before taking a break?

Community protocols usually run 4 to 8 weeks followed by at least 4 weeks off. Some logs mention 12-week runs, but there is no human data supporting longer use. Long-term safety of injected MOTS-c in humans is unknown.

Is MOTS-c legal to buy in the United States?

MOTS-c is not FDA-approved for human use and is legally sold only as a research chemical, not as a supplement or drug. Buying it for personal injection sits in a regulatory gray area, and imported shipments can be seized. Products sold for human consumption would be considered misbranded.